Augmedix (AUGX) to Release Earnings on Monday

Augmedix (NASDAQ:AUGX - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday, May 13th. Analysts expect Augmedix to post earnings of ($0.12) per share for the quarter. Augmedix has set its FY 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

Augmedix (NASDAQ:AUGX - Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.09) EPS for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The company had revenue of $12.68 million during the quarter, compared to the consensus estimate of $12.30 million.

Augmedix Trading Down 0.4 %

NASDAQ AUGX traded down $0.01 during trading on Monday, hitting $2.70. The company had a trading volume of 161,591 shares, compared to its average volume of 364,860. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.66. Augmedix has a one year low of $2.50 and a one year high of $6.25. The company has a market cap of $132.22 million, a price-to-earnings ratio of -6.04 and a beta of 0.03. The company's fifty day moving average is $3.66 and its 200-day moving average is $4.58.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Evercore ISI upgraded shares of Augmedix from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $4.50 to $5.00 in a research note on Tuesday, April 9th. B. Riley assumed coverage on shares of Augmedix in a research note on Wednesday, April 3rd. They issued a "buy" rating and a $5.50 price target for the company. Finally, Maxim Group decreased their price target on shares of Augmedix from $6.50 to $5.00 and set a "buy" rating for the company in a research note on Tuesday, March 19th.

Insider Activity

In other news, insider Ian Shakil sold 58,978 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $3.91, for a total transaction of $230,603.98. Following the sale, the insider now owns 180,034 shares of the company's stock, valued at approximately $703,932.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 251,323 shares of company stock valued at $1,005,527 in the last 90 days. 10.97% of the stock is currently owned by insiders.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.